High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory cushing disease from capecitabine and temozolomide (CAPTEM): A case series

Neurosurgery

Volumn 74, Issue 4, 2014, Pages

  Zacharia, Brad E ^a   Gulati, Anthony P ^a   Bruce, Jeffrey N ^a   Carminucci, Arthur S ^a   Wardlaw, Sharon L ^b   Siegelin, Markus ^c   Remotti, Helen ^c   Lignelli, Angela ^b   Fine, Robert L ^a,d  

^a Department of Neurological Surgery Pancreas Center at Columbia ^*  (United States)

^b Department of Medicine Neuroendocrine Unit   (United States)

^c Department of Orthopaedic Surgery   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CAPECITABINE; CORTICOTROPIN; DEXAMETHASONE; FLUORODEOXYGLUCOSE; HYDROCORTISONE; KETOCONAZOLE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METYRAPONE; MISMATCH REPAIR PROTEIN PMS2; OCTREOTIDE; PASIREOTIDE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DEOXYCYTIDINE; FLUOROURACIL;

ABDUCENS NERVE; ABSENCE OF SIDE EFFECTS; ACTH SECRETING ADENOMA; ADRENALECTOMY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CAVERNOUS SINUS; CLIVUS; COMPUTER ASSISTED RADIOTHERAPY; CUSHING DISEASE; CUSHING SYNDROME; CYTOREDUCTIVE SURGERY; DIARRHEA; DIPLOPIA; DRUG EFFICACY; DYSPHAGIA; EXTERNAL BEAM RADIOTHERAPY; FACIAL NERVE; FEBRILE NEUTROPENIA; FEMALE; GAMMA KNIFE RADIOSURGERY; HEADACHE; HUMAN; HYPOPHYSECTOMY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NERVE COMPRESSION; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOGRAPHY; REMISSION; SELLA TURCICA; SKULL BASE; SPHENOID SINUS; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR INVASION; TUMOR REGRESSION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ANALOGS AND DERIVATIVES; PATHOLOGY; PITUITARY ACTH HYPERSECRETION;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; DACARBAZINE; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION;

EID: 84897378289     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000251     Document Type: Article

References (36)

1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613-619.
2. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994;120(10):817-820.
3. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90(5):3089-3099.
4. Kovacs K, Horvath E, Vidal S. Classification of pituitary adenomas. JNeurooncol 2001;54(2):121-127.
5. Ironside JW. Best Practice No 172: pituitary gland pathology. J Clin Pathol. 2003; 56(8):561-568.
6. Bertagna X, Guignat L. Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery.J Clin Endocrinol Metab. 2013; 98(4):1307-1318.
7. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome.J Clin Endocrinol Metab. 2001;86(9):4104-4108.
8. Miehle K, Tannapfel A, Lamesch P, et al. Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence. J Clin Endocrinol Metab. 2004;89(8):3731-3736.
9. Uwaifo GI, Koch CA, Hirshberg B, et al. Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome? J Endocrinol Invest. 2003;26(8):710-717.
10. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary. 2011;14(4):418-424.
11. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol. ASCO Annual Meeting Proceedings. 2005;23(16S):4216.
12. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12(8):1139-1143.
13. Balmaceda C, Peereboom D, Pannullo S, et al. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008;112(5):1139-1146.
14. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once-and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 2001;7(8):2309-2317.
15. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663-670.
16. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268-275.
17. Isacoff WH, Pecora AL, Fine RL. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas: a retrospective review. J Clin Oncol. 2006;24(18S).
18. Gulati AP, Krantz B, Moss RA, et al. Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology. 2013;84(3):127-134.
19. Melcescu E, Gannon AW, Parent AD, et al. Silent or subclinical corticotroph pituitary macroadenoma transforming into Cushing disease: 11-year follow-up. Neurosurgery. 2013;72(1):E144-E146.
20. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518-520.
21. Fadul CE, Kominsky AL, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide: report of two cases. J Neurosurg 2006;105(4):621-626.
22. Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007;38(1):185-189.
23. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631-637.
24. Byrne S, Karapetis C, Vrodos N. A novel use of temozolomide in a patient with malignant prolactinoma.J Clin Neurosci. 2009;16(12):1694-1696.
25. McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009;71(2):226-233.
26. Neff LM, Weil M, Cole A, et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary. 2007;10(1):81-86.
27. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery. 2009;64 (4):E773-E774; discussion E774.
28. Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA, Fleseriu M. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary. 2011;14(1):80-91.
29. Annamalai AK, Dean AF, Kandasamy N, et al. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary. 2012;15(3):276-287.
30. Curtò L, Torre ML, Ferraù F, et al. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease: report of a case and literature review. Scientific World Journal. 2010;10:2132-2138.
31. Bode H, Seiz M, Lammert A, et al. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes. 2010;118 (10):760-763.
32. Phillips J, East HE, French SE, et al. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Hormones (Athens). 2012;11(4):477-482.
33. Moshkin O, Syro LV, Scheithauer BW, et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens). 2011;10(2):162-167.
34. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348-1354.
35. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15 (1):338-345.
36. Salehi F, Scheithauer BW, Kovacs K, et al. O-6-methylguanine-DNA methyl-transferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery. 2012;70(2):491-496; discussion 496.